Short answer
Dyne Therapeutics, Inc. (DYN) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Full-year 2025 financial results announced March 2, 2026; details in Exhibit 99.1 press release.
Dyne Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 financial results announced March 2, 2026; details in Exhibit 99.1 press release
- Filing furnished (not filed): limits legal liability but does not affect investor relevance of results
- Dyne is a clinical-stage rare disease company; annual results signal cash runway and pipeline progress
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dyne Therapeutics, Inc. 8-K filings
Get the next DYN 8-K as it lands
Follow DYN for push alerts, or ask the research agent what this filing means.